Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTX2735 in CAPS
NCT05812781Phase 2Completed
- Sponsor
- Zomagen Biosciences
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VTX2735 in cryopyrin-associated periodic syndrome (CAPS), familial cold autoinflammatory syndrome (FCAS), sponsored by Zomagen Biosciences. Started Mar 2023; status: completed.
02
Drugs
VTX2735
03
Conditions
cryopyrin-associated periodic syndrome (CAPS)familial cold autoinflammatory syndrome (FCAS)
Beyond the preview
Go deeper on NCT05812781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05812781.